I：根据JCR分类的期刊的影响因子、全称相关的问题，练习使用JCR和作者查询；5%--5道题II：根据Web of Science搜索作者+单位+领域得到的文章及被引次数的问题；5%--5道题III：一篇Title+Abstract的划分几部分，每部分分别到哪里相关的问题；P20810%--5道题Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. AbstractWithout an approved vaccine or treatments,Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission.These approaches,however,have yet to end the2014outbreak of Ebola after its prolonged presence in West Africa.／Here we show that a combination of monoclonal antibodies(ZMapp),optimized from two previous antibody cocktails,is able to rescue 100%of rhesus macaques when treatment is initiated up to5days post-challenge.／High fever,viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention.Advanced disease,as indicated by elevated liver enzymes,mucosal haemorrhages and generalized petechia could be reversed,leading to full recovery.ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola.／ZMapp exceeds the efficacy of any other therapeutics described so far,and results warrant further development of this cocktail for clinical use.Questions：11.Among the eight types of titles,which type does this title belong to?A:noun phrase and prepositional phrase.12.How many parts can you divide the abstract into Name each part?A:Four parts.1.Background,2.objective,3.Methods and Reults,4.Conclusion.13.What is the objective of the study?A:Here we show that…up to5days post-challenge.14.What are the results?A:Advanced disease…with the Guinean variant of Ebola.15.In the sentence,”Advanced disease,as indicated by elevated liver enzymes,mucosal haemorrhages and generalized petechia could be reversed,leading to full recovery.”Please translate the term“generalized petechia”into Chinese?A:全身瘀斑IV：最后一次课，无PPT一篇Introduction+Reference Title：P21720%--10道题IntroductionEbola virus(EBOV)infections cause severe illness in humans,and after an incubation period of3to21days,patients initially present with general flu-like symptoms beforea rapid progression to advanced disease characterized by hemorrhage,multi-organ failure and a shock-like syndrome1.In the spring of2014,a new EBOV variant emerged in the West African country of Guinea2,an area in which EBOV has not been previously reported.Despite a sustained international response from local and international authorities including the Ministry of Health(MOH),World Health Organization(WHO)and Médecins Sans Frontières(MSF)since March2014,the outbreak has yet to be brought to an end after five months.As of15th August2014, there are2127total cases and1145deaths spanning Guinea,Sierra Leone,Liberia and Nigeria3.So far,this outbreak has set the record for the largest number of cases and fatalities,in addition to geographical spread4.Controlling an EBOV outbreak of this magnitude has proven to be a challenge and the outbreak is predicted to last for at least several more months5.In the absence of licensed vaccines and therapeutics against EBOV,there is little that can be done for infected patients outside of supportive care,which includes fluid replenishment,administration of antivirals,and management of secondary symptoms6,7.With overburdened personnel,and strained local and international resources,experimental treatment options cannot be considered for compassionate use in an orderly fashion at the moment.However,moving promising strategies forward through the regulatory process of clinical development has never been more urgent.Over the past decade,several experimental strategies have shown promise in treating EBOV-challenged nonhuman primates(NHPs)after infection.These include recombinant human activated protein C(rhAPC)8,recombinant nematode anticoagulant protein c2(rNAPc2)9,small interfering RNA(siRNA)10,positively-charged phosphorodiamidate morpholino oligomers(PMO plus)11,the vesicular stomatitis virus vaccine(VSVΔG-EBOVGP)12,as well as the monoclonal antibody(mAb)cocktails MB-003(consisting of human or human-mouse chimeric mAbs c13C6,h13F6and c6D8)13and ZMAb(consisting of murine mAbs m1H3,m2G4and m4G7)14.Of these,only the antibody-based candidates have demonstrated substantial benefits in NHPs when administered greater than24hours past EBOV exposure.Follow-up studies have shown that MB-003is partially efficacious when administered therapeutically after the detection of two disease“triggers”15,and ZMAb combined with an adenovirus-based adjuvant provides full protection in rhesus macaques when given up to72hours after infection16.The current objective is to develop a therapeutic superior to both MB-003and ZMAb, which could be utilized for outbreak patients,primary health-care providers,as well as high-containment laboratory workers in the future.This study aims to first identify an optimized antibody combination derived from MB-003and ZMAb components, before determining the therapeutic limit of this mAb cocktail in a subsequent experiment.In order to extend the antibody half-life in humans and to facilitate clinical acceptance,the individual murine antibodies in ZMAb were first chimerized with human constant regions(cZMAb).The cZMAb components were then producedin Nicotiana benthamiana17,using the large-scale,cGMP-compatible Rapid Antibody Manufacturing Platform(RAMP)and magnICON vectors that currently also manufactures the individual components of cocktail MB-003,before efficacy testing in animals.References1.Bausch DG,Sprecher AG,Jeffs B,Boumandouki P.Treatment of Marburg and Ebola hemorrhagic fevers:a strategy for testing new drugs and vaccines under outbreak conditions.Antiviral Res.2008;78:150–161.doi:10.1016/j.antiviral.2008.01.152.[PubMed][Cross Ref]2.Baize S,et al.Emergence of Zaire Ebola Virus Disease in Guinea-Preliminary Report.N Engl J Med.2014doi:10.1056/NEJMoa1404505.[PubMed][Cross Ref]3.WHO.int.WHO-Ebola virus disease(EVD)2014<http://www.who.int/csr/don/archive/disease/ebola/en/>..Chronology of Ebola Hemorrhagic FeverOutbreaks.2014</vhf/ebola/resources/outbreak-table.html>.5.Reliefweb.int.W.African Ebola epidemic‘likely to last months’:UN.2014<http://reliefweb.int/report/guinea/w-african-ebola-epidemic-likely-last-mo nths-un>.6.Clark DV,Jahrling PB,Lawler JV.Clinical management of filovirus-infected patients.Viruses.2012;4:1668–1686.doi:10.3390/v4091668.[PMC freearticle][PubMed][Cross Ref]7.Guimard Y,et anization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit,Democratic Republic of the Congo,1995.J InfectDis.1999;179(Suppl1):S268–273.doi:10.1086/514315.[PubMed][Cross Ref]8.Hensley LE,et al.Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.J Infect Dis.2007;196(Suppl2):S390–399.doi: 10.1086/520598.[PubMed][Cross Ref]9.Geisbert TW,et al.Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor:a study in rhesus ncet.2003;362:1953–1958. doi:10.1016/S0140-6736(03)15012-X.[PubMed][Cross Ref]10.Geisbert TW,et al.Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference:a proof-of-conceptncet.2010;375:1896–1905.doi:10.1016/S0140-6736(10)60357-1.[PubMed][Cross Ref]Questions:16.What is the difference between abstract and introduction?A:There are no references in the abstract and no results in introduction.17.How many parts can you divide the introduction into?Name each part?A:Four Parts.Background,Conclusion,Objective,Method18.What problem is posed on this article?A:The current objective is to develop a therapeutic superior to both MB-003and ZMAb,which could be utilized for outbreak patients,primary health-care providers, as well as high-containment laboratory workers in the future.19.In the first paragragh,what does“supportive care”refer to?A:It includes fluid replenishment,administration of antivirals,and management of secondary symptoms20.What style of referencing system does it belong to?A:Citation order system.21.How many authors are listed in item1?A:Four.22.Where is the article published in Item2?A:New England Journal of Medicine.23.What kind of the reference source does item3belong to?24.What type does the title belong to in item10?A:Title and subtitle25.Please translate the Chinese title“肝素疗法的前瞻性随机研究：into English by using the same method as Item10.A:Heparin therapy:Prospective randomized studyVI：Journal Instruction for authors：10%--11道题General InformationJAMA Internal Medicine is an international peer-reviewed journal providing innovative and clinically relevant research for practitioners in general internal medicine and internal medicine subspecialities. The Editor of JAMA Internal Medicine is Rita F.Redberg,MD,MSc,University of California San Francisco School of Medicine,San Francisco,California.The journal is published online every Monday and in print each month.Authorship Criteria and Conditions and Authorship FormEach author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.One or more of the authors should take responsibility for the integrity of the work as a whole,from inception to published article.1,2According to the guidelines of the International Committee of Medical Journal Editors(ICMJE),as revised in2013,2authorship credit should be based on the following4criteria:(1)substantial contributions to conception or design of the work,or the acquisition,analysis,or interpretation of data for the work;and(2)drafting of the work or revising it critically for important intellectual content;and(3)final approval of the version to be published;and(4)agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Each author should be accountable for the parts of the work he or she has done.In addition,each author should be able to identify which coauthors are responsible for specific other parts of the work and should have confidence in the integrity of the contributions of any coauthors.Changes in AuthorshipAuthors should determine the order of authorship among themselves and should settle any disagreements among themselves before submitting their manuscripts.Changes in authorship(ie,order,addition,and deletion of authors)should be discussed and approved by all authors.Any requests for such changes in authorship after initial manuscript submission and before publication should be explained in writing to the editor in a letter or email from all authors.1(pp134-135)Manuscript SubmissionManuscripts should be submitted online via the online manuscript submission and review system.At the time of submission,complete contact information(affiliation,postal/mail address,e-mail address, telephone and fax numbers)for the corresponding author is required.First and last names,e-mail addresses,and institutional affiliations of all coauthors are also required.Manuscripts submitted through the online system should not also be submitted by mail or e-mail.After the manuscript is submitted,the corresponding author will receive an acknowledgment confirming receipt and a manuscript number.Authors will be able to track the status of their manuscripts via the online system. After manuscript submission,all authors of Letters to the Editor and Invited Commentaries will be sent an Authorship Form to complete and submit(see sample Authorship Form).All authors of all other manuscripts will receive an Authorship Form at the time of request for/receipt of a revision to their manuscript.See Manuscript Checklist,Manuscript Preparation and Submission Requirements,1,2and other details in these instructions for additional requirements.Manuscript StyleManuscripts should be prepared in accordance with the AMA Manual of Style,10th edition,1and/or the ICMJE Recommendations for the Conduct,Reporting,Editing,and Publication of Scholarly Work in Medical Journals.TitleTitles should be concise,specific,and informative and should contain the key points of the work.1(p8) Please limit the length of titles to150characters for reports of research and other major articles and 100characters for Editorials,Viewpoints,Commentaries,and Letters.For scientific manuscripts, overly general titles are not desirable and questions and declarative sentences should be avoided.For reports of clinical trials,meta-analyses,and systematic reviews,include the type of study as a subtitle (eg,A Randomized Clinical Trial,A Meta-analysis,A Systematic Review).For reports of other types of research,do not include study type or design in the title or subtitleReferencesAuthors are responsible for the accuracy and completeness of the references and for their correct text citation.Cite all references in the text or tables.Number references in the order they appear in the text;do not alphabetize.In text,tables,and legends,identify references with superscript arabic numerals.When listing references,follow AMA style1(pp39-79)and abbreviate names of journals according to the journals list in PubMed.List all authors and/or editors up to6;if more than6,list the first3followed by“et al.”Note:Journal references should include the issue number in parentheses after the volume number.Examples of reference style:1.Garbutt JM,Banister C,Spitznagel E,Piccirillo JF.Amoxicillin for acute rhinosinusitis:a randomized controlled trial.JAMA.2012;307(7):685-692.2.Centers for Medicare&Medicaid Services.CMS proposals to implement certain disclosure provisions of the Affordable Care Act./apps/media/press/factsheet.asp?Counter=4221.Accessed January30,2012.3.McPhee SJ,Winker MA,Rabow MW,Pantilat SZ,Markowitz AJ,eds.Care at the Close of Life: Evidence and Experience.New York,NY:McGraw Hill Medical;2011.Questions:25.What kinds of articles does JAMA provide?A:They provide innovative and clinically relevant research for practitioners in general internal medicine and internal medicine subspecialities.26.How many criteria are the authorship credit based on?A:There are4criteria.27.What is required if there are changes in authorship?A:Any requests for such changes in authorship after initial manuscript submission and before publication should be explained in writing to the editor in a letter or email from all authors28.Can authors submit their articles via mail or e-mail?A:No29.How do authors know the status of their manuscript?A:Authors will be able to track the status of their manuscripts via the online system30.What is the requirement for the title of reports of research and other major articles?A:Please limit the length of titles to150characters for reports of research and other major articles 31.Structured abstract can be further divided into two kinds.What are they?A:The first kind is divided into five parts:Background,Objective,Methods,Results and Conclusion and the other one is divided into four parts:Objective,Methods,Results and Conclusion.32.In test,tables,and legends,how are the references identified?A:In text,tables,and legends,identify references with superscript arabic numerals.33.If the authors are more than six,how to list the authors’name?A:if more than6,list the first3followed by“et al.”34.In reference Item3,what is“Care at the Close of Life:Evidence and Experience”?A:The name of the cited book.35.In reference Item3,NY:McGraw Hill Medical is publisher.。